期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 348, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2020.577383
关键词
Myasthenia gravis; Rituximab; microRNA; Exosome
资金
- National Natural Science Foundation of China [81870988, 81701236]
- National Key Research and Development Program of China [2016YFC0901504]
- Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). In this prospective, open-label, and self-controlled pilot trial, 12 AChR-positive refractory MG patients were administrated a single, low dose of RTX and followed up at six months. Results showed that RTX decreased the serum exosomal miR-150-5p, scores on three clinical indices (MGFA, MMT, ADL), and patients' prednisolone requirement. Additionally, CD19 + and CD27+ B cells decreased, showing a strong correlation with miR-150-5p. In conclusion, low-dose RTX is effective for AChR-positive refractory MG treatment. Furthermore, our data support the role of miR-150-5p as a potential biomarker for MG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据